rEVO sets IPO terms

rEVO Biologics Inc., a subsidiary of LFB S.A. (Les Ulis, France), set the terms for its IPO on NASDAQ. It plans to sell 3.6 million shares at $13-$15. LFB plans to purchase $10 million of the IPO shares and invest $10 million in a concurrent private placement at the IPO price. At the $14 midpoint, the company would raise $60.4 million including the placement, and be valued at $258.1 million. Piper Jaffray; Guggenheim Securities; Roth Capital Partners; and BTIG are underwriters. ...